SYNACT PHARMA ApS
CVR number: 34459975
Dronninggårds Alle 136, 2840 Holte
joo@txppharma.com
tel: 28447567
Income statement (kDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | -11 468.38 | -16 674.00 | -43 429.98 | -46 951.48 | -63 448.35 |
| Employee benefit expenses | -2 647.44 | -7 454.00 | -6 409.70 | ||
| Total depreciation | - 238.67 | - 287.00 | - 472.09 | - 816.86 | -1 011.14 |
| EBIT | -11 707.05 | -16 961.00 | -46 549.51 | -55 222.33 | -70 869.19 |
| Other financial income | 125.32 | 4.00 | 0.08 | 221.84 | 53.61 |
| Other financial expenses | - 463.09 | - 424.00 | - 108.82 | - 279.81 | -93.34 |
| Pre-tax profit | -12 044.82 | -17 381.00 | -46 658.26 | -55 280.30 | -70 908.93 |
| Income taxes | 2 218.51 | 3 379.00 | 5 501.63 | 5 500.00 | 5 500.00 |
| Net earnings | -9 826.31 | -14 002.00 | -41 156.63 | -49 780.30 | -65 408.93 |
Assets (kDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Development expenditure | 932.52 | 1 485.00 | 3 090.18 | 4 626.17 | 6 291.49 |
| Intangible assets total | 932.52 | 1 485.00 | 3 090.18 | 4 626.17 | 6 291.49 |
| Machinery and equipment | 9.56 | 3.00 | |||
| Tangible assets total | 9.56 | 3.00 | |||
| Other receivables | 92.43 | 158.00 | 199.49 | 180.31 | 93.49 |
| Investments total | 92.43 | 158.00 | 199.49 | 180.31 | 93.49 |
| Long term receivables total | |||||
| Inventories total | |||||
| Current trade debtors | 11 616.60 | ||||
| Current amounts owed by group member comp. | 127.00 | ||||
| Prepayments and accrued income | 93.42 | 107.00 | 203.31 | 46.02 | 67.06 |
| Current other receivables | 407.61 | 981.00 | 1 631.68 | 2 828.29 | 2 694.16 |
| Current deferred tax assets | 2 218.51 | 3 378.00 | 5 500.00 | 5 500.00 | 5 500.00 |
| Short term receivables total | 2 719.54 | 4 593.00 | 7 334.99 | 19 990.92 | 8 261.23 |
| Cash and bank deposits | 2 321.93 | 6 452.00 | 2 919.44 | 13 149.75 | 12 138.68 |
| Cash and cash equivalents | 2 321.93 | 6 452.00 | 2 919.44 | 13 149.75 | 12 138.68 |
| Balance sheet total (assets) | 6 075.98 | 12 691.00 | 13 544.10 | 37 947.15 | 26 784.89 |
Equity and liabilities (kDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Share capital | 1 000.00 | 1 000.00 | 1 000.00 | 1 000.00 | 1 000.00 |
| Share premium account | 17 060.00 | 17 060.00 | 17 060.00 | ||
| Asset revaluation reserve | 83 635.02 | 160 761.18 | 207 761.18 | ||
| Retained earnings | -13 000.74 | 24 360.00 | -53 889.36 | -95 045.99 | - 144 826.29 |
| Profit of the financial year | -9 826.31 | -14 002.00 | -41 156.63 | -49 780.30 | -65 408.93 |
| Shareholders equity total | -21 827.05 | 11 358.00 | 6 649.03 | 33 994.89 | 15 585.96 |
| Provisions | 100.00 | 4 027.09 | |||
| Non-current liabilities total | |||||
| Current loans from credit institutions | 69.54 | ||||
| Current trade creditors | 1 204.91 | 1 333.00 | 5 363.01 | 2 439.60 | 6 062.02 |
| Current owed to group member | 26 628.58 | 1.02 | |||
| Other non-interest bearing current liabilities | 1 531.04 | 1 412.67 | 1 109.82 | ||
| Current liabilities total | 27 903.03 | 1 333.00 | 6 895.07 | 3 852.26 | 7 171.84 |
| Balance sheet total (liabilities) | 6 075.98 | 12 691.00 | 13 544.10 | 37 947.15 | 26 784.89 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.